MacroGenics, Inc. Stock Prediction
AI-powered sentiment analysis and prediction trends for MGNX, updated each market day.
MGNX AI Sentiment
AI sees no strong directional signal for MacroGenics, Inc. stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About MacroGenics, Inc.
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.
Sector
Exchange
Market Cap
$218,646,633
Cap Tier
Employees
293
Headquarters
Rockville, MD
Listed Since
Oct. 10, 2013
Website
MGNX Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
MGNX Volatility
MacroGenics, Inc. has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
